Laboratoires Pierre Fabre confirms the strength of its business model and is stepping up its investments in innovation and production

A group firmly focused on the international market

71% of the company’s 2025 revenue was generated internationally through 43 subsidiaries spread across five continents and product distribution covering 130 territories. To put this in perspective, the international share of the company’s revenue was 64% in 2019 and 69% in 2023, confirming the company’s resolute shift toward an international focus over the years.

The Pharmaceuticals business benefits from the strong momentum of its Oncology product portfolio, whose revenues grew by 8.6% in 2025. 

Between 2018 and 2025, Oncology’s share of the pharmaceutical business’s revenue thus rose from 19% to 41%. This growth stems primarily from the launch in Europe of targeted therapies for the treatment of cancers with rare B-RAF cell mutations ( : melanoma, colorectal cancer, non-small cell lung cancer). In China, the launch of these therapies for B-RAF-mutated colorectal cancer also began following the granting of marketing authorization in June 2025. Marketing authorization is also expected in 2026 for B-RAF-mutated non-small cell lung cancer (NSCLC). 

Revenues from Medical Dermatology and Primary Care products also increased by 6% and 2%, respectively. Primary Care benefited from the European launch of a new urology treatment for overactive bladder. Medical Dermatology benefited from the expansion of its actinic keratosis treatment in the United Kingdom, as well as the European launch of a new acne care range under the Dexeryl brand.  

The dermo-cosmetics business is reaping the rewards of a strategy implemented over the past three years that has focused on reinforcing its medical mission and leveraging the unique expertise of its brands in skin and scalp care.

In 2025, particularly strong results were recorded in Asia (+10.8%) and, to a lesser extent, in Europe (+3.7%). Growth in Asia was driven by strong growth in China (+12.7%), while Europe benefited from robust momentum in Southern markets, with Spain posting remarkable growth of 13.1%. Pierre Fabre Dermo-Cosmetics thus confirmed its position as No. 1 in Europe in the skin repair, body atopy, and hair care segments, No. 2 in sun protection products, and No. 3 in anti-acne care¹.

Driven by its new communication platform—“Born from skin medicine”—and the launches of Hyaluron Activ Procedure (anti-aging skincare) and Cleanance Comedomed (anti-acne skincare), Eau Thermale Avène achieved 3.9% growth, with peaks of 10.7% in China and 9.2% in the United States. Eau Thermale Avène confirms its position as the group’s leading brand, with sales exceeding €1 billion, and as the second-largest brand in the European market.

Ducray posted growth that was twice the market average of 9.3%, driven by the performance of the Kelual line in the anti-dandruff shampoo segment and the Keracnyl line in the anti-acne care segment. A-Derma grew by 4.9% thanks to the launch of the Exomega Control emollient night cream in the atopic dermatitis segment. Même Cosmetics, a niche brand specializing in skincare products to support cancer treatments, achieved remarkable growth of 42%. 

The year 2025 was also marked by increased investment in pharmaceutical and dermo-cosmetic  R&D.  

• Investments in pharmaceutical R&D increased by 14% compared to the previous year. Representing 13.6% of the business’s revenue, 89% of    these investments were focused on precision oncology.    
• Collaboration agreements continued with the biotech companies Vernalis, RedRidge, and Iktos to identify and develop new drug candidates in oncology, dermatology, and rare diseases.
• The Pharmaceutical business’s pipeline now includes 5 molecules in clinical development and 6 research programs in the preclinical phase.  
• Investments in dermo-cosmetic R&D accounted for 3.6% of the business’s revenue, focusing on seven priority segments: acne, atopic dermatitis, skin repair, sun protection, skin aging, seborrheic dermatitis, and alopecia.

In 2025, Pierre Fabre Laboratories filed 35 patent applications, thereby returning to the list of the top 50 patent applicants published annually by the National Institute of Intellectual Property (INPI). The company ranks third in this ranking for the cosmetics sector alone.

Sustained industrial investments to support future growth

Operations has also seen significant investments as part of its industrial master plan, totaling €250 million for the 2023–2027 period. In 2025, the main investments focused on continuing the dry plant project at the Soual site (Tarn), which is expected to be completed in 2026, the installation of a regenerative thermal oxidizer at the Gaillac site (Tarn), and the expansion project for the Avène plant (Hérault), which is expected to be completed in 2027.  

A CSR commitment recognized at the highest level

In December 2025, Laboratoires Pierre Fabre’s CSR approach was once again assessed by AFNOR Certification at the “Exemplary” level of the Engagé RSE label (ISO 26000 standard for sustainable development). This certification specifically recognizes the company’s efforts in adapting to climate change. Energy consumption and carbon emissions have thus decreased by 34% and 27%, respectively, since 2015, while water consumption has fallen by 34% since 2018. On another note, the official index measuring gender equality rose by 5 points during 2025 to reach a score of 99/100. 
 

Contact presse :
Dorothée Kohler
dorothee.kohler@pierre-fabre.com 
06 08 09 22 41

1  Source: IQVIA Europe 15